Menagen Pharmaceutical Industries and South Korea-based Chong Kun Dang Pharmaceutical (CKD) Korea entered into a strategic Middle Eastern regional market partnership for the technology transfer, manufacture, and commercialization of a Darbepoetin alpha biosimilar. The product is a second-generation epoetin indicated for the treatment of anemia associated with chronic renal failure. The CKD biosimilar is currently approved in South Korea.
Menagen runs a state-of-the-art biomanufacturing facility in Muscat, Oman covering an area of 32,000 ft². The company focuses on various niche therapeutic products, including, but not limited to biosimilars, oncology, hematology, nephrology, orphan and other medicines.
“Through this collaboration with CKD we are establishing our biosimilar footprint in the Middle East and Africa markets and reaching more people living with severe chronic diseases,” said Rula Fahoom, vice president of business development at Menagen. “We aim to provide broad access to patients with unmet medical needs by leveraging Mengen’s local expertise and capabilities.”
